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Background: Staphylococcus aureus (SA) is an important pathogen among patients with cystic fibrosis (CF). Inducible clindamycin
resistance (ICR) has been described as a cause of treatment failure in non-CF related infections. The prevalence of ICR among SA from
patients with CF is unknown.
Methods: We compared clindamycin susceptibilities of SA isolated from patients with and without cystic fibrosis (CF) using hospital
microbiology data. Patients with CF were primarily identified using CF registry data. We evaluated all patients who had SA isolated at the
Children's Healthcare of Atlanta microbiology laboratory during May 2004–May 2005. We performed antimicrobial susceptibility testing
using broth microdilution and performed D-zone testing for ICR in accordance with the Clinical Laboratory Standards Institute (CLSI)
document M100-S16. Proportions were compared using a 2-sided Pearson's Chi-square test or Fisher's exact test to assess for significance.
Results: Of 703 patients with methicillin-resistant SA (MRSA), 48% of CF patients (68/143) had at least one isolate demonstrating ICR,
compared to 8% of non-CF patients (43/560) (Pb0.01). Of 762 patients with methicillin-susceptible SA (MSSA), 29% of CF patients (73/
254) had at least one isolate demonstrating ICR compared to 17% of non-CF patients (88/508) (Pb0.01).
Conclusions: SA demonstrating ICR are significantly more prevalent among patients with CF than among those without CF.
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Staphylococcus aureus (SA) is an important pathogen
among patients with cystic fibrosis (CF) [1]. SA often is the
first organism isolated from children with CF, and is the
second most commonly isolated organism in CF patients
overall. Drug resistant SA frequently is encountered in CF☆ These data were presented at the Infectious Disease Society of America
44th Annual Meeting, October 12–15, 2006, Toronto, Ontario.
⁎ Corresponding author. 1902 Mail Service Center, Raleigh, NC 27699-
1902, United States. Tel.: +1 919 715 4698; fax: +1 919 715 4699.
E-mail address: ZMoore@cdc.gov (Z.S. Moore).
1 Current affiliation: Epidemic Intelligence Service, Centers for Disease
Control and Prevention.
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doi:10.1016/j.jcf.2007.07.010patients, and has been attributed to antibiotic selection
pressure [2] and a high proportion of hypermutable strains
[3]. The prevalence of methicillin-resistant SA (MRSA)
colonization among CF patients varies by region [4] and is of
debatable clinical significance [5]. However, a recent large,
observational study demonstrated more severe airflow
obstruction among CF patients with only MRSA in
respiratory tract cultures compared to those with methicil-
lin-susceptible SA (MSSA) [6]. In addition, MRSA
colonization may lead to increased glycopeptide use,
necessitate increased infection control measures, and
adversely affect eligibility for lung transplantation [5].
The Macrolide–Lincosamide–Streptogramin B (MLSB)
resistance phenotype frequently is recognized among SA and
may be constitutive or inducible. Resistance due to MLSBed by Elsevier B.V. All rights reserved.
Table 1
Clindamycin susceptibility of methicillin-resistant S. aureus (MRSA) and
methicillin-susceptible S. aureus (MSSA) isolates from cystic fibrosis (CF)
and non-CF patients
MRSA MSSA
CF
No. (%)
Non-CF
No. (%)
P
value
CF
No. (%)
Non-CF
No. (%)
P
value
Susceptible a 18 (13) 450 (80) b0.01 155 (61) 408 (80) b0.01
Intermediate 0 (0) 2 (0) – 1 (0) 2 (0) –
Resistant b 57 (40) 65 (12) b0.01 25 (10) 10 (2) b0.01
ICR c 68 (48) 43 (8) b0.01 73 (29) 88 (17) b0.01
Total 143 (100) 560 (100) 254 (100) 508 (100)
a Denotes patients with all isolates fully susceptible to clindamycin.
b Denotes patients with no isolates demonstrating inducible clindamycin
resistance and at least one isolate demonstrating constitutive clindamycin
resistance.
c Denotes patients with at least one isolate demonstrating inducible
clindamycin resistance.
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mediated by erythromycin ribosomal methylase (erm) genes.
SA with the inducible MLSB phenotype are susceptible to
clindamycin and resistant to erythromycin on initial in vitro
testing, but may become resistant to clindamycin following
exposure to clindamycin. Inducible clindamycin resistance
(ICR) has been recognized as a cause of treatment failure [7].
The presence of ICR can be determined in vitro by use of the
D-zone test [8]. Many laboratories do not perform D-zone
testing routinely, and may report these isolates as clindamy-
cin susceptible. The reported prevalence of ICR among SA
varies from b5% to N90% in different populations [9–11].
The prevalence of ICR among SA isolated from CF patients
is not known. In this study, we compared the prevalence of
ICR among MRSA and MSSA isolated from patients with
CF to the prevalence among isolates from non-CF patients.
2. Methods
All SA isolated from any culture type at the Children's
Healthcare of Atlanta (CHOA) microbiology laboratories
between May 1st, 2004 and May 31st, 2005 were evaluated.
Antimicrobial susceptibility testing was done using a
commercial broth microdilution method (MicroScan, Dade
Behring, West Sacramento, CA). D-zone testing for ICR was
performed according to previously published methods [8] for
all isolates demonstrating susceptibility to clindamycin (MIC
≤0.5 mcg/mL) and resistance to erythromycin (MIC
≥8 mcg/mL) [12].
Patients with CF were identified using CF registry data
from the Emory Cystic Fibrosis Center and the CHOA
Scottish Rite Affiliate Program, two separate programs
which both utilize the CHOAmicrobiology laboratories. The
CHOA microbiology laboratories serve the Egleston Chil-
dren's Hospital at Emory as well as Scottish Rite Children's
Hospital under the direction of one clinical microbiologist
and utilize one set of standard operating procedures. CF
patients were also identified by reviewing medical records of
all patients who had SA isolated from respiratory cultures
designated as “CF cultures”. CF cultures are performed on
respiratory tract specimens only, and are plated on Bur-
kholderia cepacia selective agar and mannitol salt agar in
addition to media used for routine respiratory tract cultures
[13]. CF cultures were incubated at least four days for
isolation of slow-growing colonies, while other respiratory
tract cultures were incubated for a minimum of two days.
Patients with other chronic lung conditions who had SA
isolated from CF cultures were analyzed with the non-CF
patient group.
One SA isolate per patient was included in the final
analysis. The isolate to be included was selected based on
clindamycin susceptibility: Isolates demonstrating ICR were
selected over constitutively resistant isolates and constitu-
tively resistant isolates were selected over susceptible
isolates regardless of culture source or date of isolation.
This was done in order to determine 1) the proportion ofpatients infected or colonized with inducibly clindamycin-
resistant SA at any point during the study period; and 2) the
proportion of patients in whom all SA isolates were fully
susceptible to clindamycin. Each patient contributed only
one isolate to the analysis regardless of the number of clinic
visits or hospital admissions.
Clindamycin susceptibility patterns of SA from patients
with CF were compared to those of SA from patients without
CF. All analyses were performed separately for MRSA and
MSSA. We also assessed for potential differences in
clindamycin susceptibility between respiratory tract and
non-respiratory tract isolates from patients without CF. For
the latter analysis, we included strict respiratory tract cultures
(i.e., sputum, bronchoalveolar lavage fluid, endotracheal tube
suctions, and oropharyngeal swabs) as well as cultures of the
ears, eyes, nose, sinuses and throat, given the likelihood of
obtaining respiratory tract flora from these sites. Isolates from
all other culture types were defined as non-respiratory.
Isolates from CF patients were excluded from this analysis.
Data were analyzed using SPSS v13.0 for Windows
(SPSS Inc., Chicago). Proportions were compared using a 2-
sided Pearson's Chi-square test to assess for significance.
Approvals were granted by the Institutional Review Boards
of Children's Healthcare of Atlanta and Emory University.
3. Results
SA was isolated from 397 patients with CF and 1068
patients without CF during the study period. Seven patients
were excluded from analysis due to missing erythromycin or
clindamycin MIC results. Among CF patients, 364 were
identified from CF registry data and 33 from chart review.
Among all SA positive patients, there was a median of 2
isolates per patient among CF patients (range 1–7) and a
median of 1 isolate per patient among non-CF patients (range
1–11) during the study period. Ninety-nine percent of SA
isolates from CF patients were obtained from induced sputa
or throat specimens obtained by trained personnel at the CF
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Another 1% of isolates from CF patients came from routine
respiratory tract cultures. SA from non-CF patients was
isolated most commonly from wound cultures (61%)
followed by respiratory tract cultures (21%) and blood
cultures (9%), with the remaining isolates from a variety of
other culture types (9%).
3.1. MRSA
MRSA was isolated from 703 patients during the study
period. ICR was detected in 48% of isolates from CF patients
(68/143) and 8% of isolates from non-CF patients (43/560)
(Table 1). Among all patients with MRSA, constitutive
clindamycin resistance was detected in an additional 40% of
isolates from CF patients and 12% of isolates from non-CF
patients. Overall, 13% of MRSA isolates from CF patients
were fully susceptible to clindamycin (18/143), compared to
80% of MRSA isolates from non-CF patients (450/560).
Among MRSA that were erythromycin-resistant and clin-
damycin susceptible by broth microdilution, 84% of isolates
from CF patients demonstrated ICR (68/81), compared with
9% of isolates from non-CF patients (43/460) (Pb0.01).
Among non-CF patients with MRSA, ICR was found in
23% of respiratory tract isolates (19/81) and 5% of non-
respiratory isolates (24/479). Among isolates that were
erythromycin-resistant and clindamycin-susceptible by broth
microdilution, 41% (19/46) of respiratory tract isolates and
6% (24/414) of non-respiratory isolates demonstrated ICR
(Pb0.01). However, MRSA isolates from CF patients were
significantly more likely to demonstrate ICR when compared
to respiratory tract MRSA isolates from non-CF patients
(84% vs. 41%, Pb0.01).
3.2. MSSA
MSSA was isolated from 762 patients during the study
period. ICR was detected in 29% of isolates from CF patients
(73/254) and 17% isolates from non-CF patients (88/508)
(Table 1). Among all patients with MSSA, constitutive
clindamycin resistance was detected in an additional 10% of
isolates from CF patients and 2% of isolates from non-CF
patients. Overall, 61% of MSSA isolates from CF patients
were fully susceptible to clindamycin (155/254), compared
with 80% of MSSA isolates from non-CF patients (408/508).
Among MSSA that were erythromycin-resistant and clin-
damycin susceptible by broth microdilution, 72% of isolates
from CF patients demonstrated ICR (73/101), compared to
55% of isolates from non-CF patients (88/160) (Pb0.01).
Among non-CF patients with MSSA, ICR was found in
20% of respiratory tract isolates (27/138) and 16% of non-
respiratory isolates (59/370). Among isolates that were
erythromycin-resistant and clindamycin-susceptible, 63%
(27/43) of respiratory tract isolates and 50% (59/117) of non-
respiratory isolates demonstrated ICR (P=0.21). There was
no significant difference in the prevalence of ICR betweenMSSA isolates from CF patients and respiratory tract MSSA
isolates from non-CF patients (72% vs. 63%, P=0.32).
4. Discussion
Our data demonstrate a high prevalence of ICR among
SA isolated from patients with CF, particularly among
MRSA. To our knowledge, this phenomenon has not been
previously reported. This high prevalence appears to be due
in part to a higher prevalence of ICR among respiratory tract
isolates compared to non-respiratory isolates. However,
MRSA isolates from CF patients were substantially more
likely to demonstrate ICR than were respiratory tract MRSA
isolates from non-CF patients.
Future studies are needed to assess potential risk factors
for colonization or infection with clindamycin-resistant SA,
including exposure to antimicrobial agents and frequency of
healthcare contact. Given the frequent and prolonged
exposures to multiple classes of antibiotics among CF
patients, it is reasonable to speculate that prior antibiotic
exposures may place them at risk for increased rates of
MLSB clindamycin resistance. In particular, recent studies
suggest that prolonged exposure to azithromycin is associ-
ated with an increased proportion of SA with the MLSB
resistance phenotype [14]. Many patients at our centers are
treated with chronic azithromycin therapy. Unfortunately,
complete data regarding prior antibiotic use were not
available for this study. Future studies are needed to better
define the effect of chronic antibiotic exposure on microbial
resistance patterns.
Recent data have highlighted the development of severe
invasive lung infections in CF patients associated with
clindamycin-susceptible MRSA strains producing Panton-
Valentine Leukocidin toxin (PVL) [15]. Clindamycin has
been shown to inhibit production of SA toxins, including
PVL [16]. Given this, along with recent data describing
decreased lung function among CF patients colonized with
MRSA [6] and the potential toxicities associated with
prolonged exposure to other MRSA active drugs including
vancomycin and linezolid, clindamycin may have an
expanding role in the treatment of some CF patients.
Our study is limited by its single center design, since rates
of MRSA colonization can vary markedly by region and
center [4]. Our study is also limited in that we included only
a single positive culture result per patient. Persistence of
infection and trends in colonization or resistance over time
could therefore not be evaluated. Molecular testing of
isolates is planned to determine which SA clones are most
prevalent among CF patients, and whether differences in
clonality could explain the high prevalence of ICR seen in
this population. This information, coupled with data
regarding the clinical and economic impact of colonization
with inducibly resistant SA, would be useful in assessing
control and outcome parameters.
Our results suggest that further data should be obtained
to evaluate the outcomes of CF patients treated with
209Z.S. Moore et al. / Journal of Cystic Fibrosis 7 (2008) 206–209clindamycin for SA infections harboring MLSB phenotypes.
Until this information is available, clindamycin should be
used cautiously for treatment of SA infections in patients
with CF unless the presence of inducible clindamycin
resistance can be excluded. D-zone testing should be
routinely performed for all SA isolated from patients with
CF if they are found to be erythromycin-resistant and
clindamycin susceptible on initial testing.
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